Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antihypertensive Dosing Trials Could Have Three-Arm, No-Placebo Design

Executive Summary

Antihypertensive drug trials incorporating three dose-ranging arms and no placebo group would give a better picture of a drug's entire dose-response relationship than current fixed-dose studies, FDA Cardio-Renal Drug Products Director Raymond Lipicky, MD, told FDA's Cardiovascular & Renal Drugs Advisory Committee.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS036804

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel